| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/15/2007 | US20070036851 Acid labile drug compositions |
| 02/15/2007 | US20070036847 Lowly irritative adhesive patch |
| 02/15/2007 | US20070036837 Dietary supplement and method for increasing the colostrum immunoglobulin levels in equine mares and other animals |
| 02/15/2007 | US20070036836 Amino acid supplementation for a healthy microbiota ecosystem |
| 02/15/2007 | US20070036751 Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies |
| 02/15/2007 | US20070036745 Polymeric materials, their preparation and use |
| 02/15/2007 | US20070036744 Treatment or prevention of respiratory viral infections with alpha thymosin peptides |
| 02/15/2007 | US20070036735 Skin external preparation |
| 02/15/2007 | US20070036732 Stable topiramate formulations |
| 02/15/2007 | US20070036720 Radiolabelled metal transport protein as imaging agent |
| 02/15/2007 | DE112005000708T5 Ionen bindende Zusammensetzung Ion scavenging composition |
| 02/15/2007 | DE10141651B4 Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung Transdermal therapeutic system (TTS) with the active ingredient fentanyl and process for its preparation |
| 02/15/2007 | CA2820233A1 Perylenequinone derivatives and uses thereof |
| 02/15/2007 | CA2659961A1 Targeted protein kinase c inhibitors and uses thereof |
| 02/15/2007 | CA2659958A1 Peptides targeted to protein kinase c isoforms and uses thereof |
| 02/15/2007 | CA2658678A1 Composition and method for prevention and treatment of type i diabetes |
| 02/15/2007 | CA2618977A1 Orally disintegratable tablet |
| 02/15/2007 | CA2618966A1 Bitterness-reducing agent |
| 02/15/2007 | CA2618093A1 Composition and method for use in cartilage affecting conditions |
| 02/15/2007 | CA2617934A1 Transdermal drug delivery formulation |
| 02/15/2007 | CA2617907A1 Triazole-containing releasable linkers and conjugates comprising the same |
| 02/15/2007 | CA2617064A1 Conjugates of a g-csf moiety and a polymer |
| 02/15/2007 | CA2616826A1 Stabilizers for veterinary vaccines |
| 02/15/2007 | CA2616810A1 Tri-block copolymers for nanosphere-based drug delivery |
| 02/15/2007 | CA2616187A1 Human growth hormone conjugated with biocompatible polymer |
| 02/15/2007 | CA2615941A1 Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor |
| 02/15/2007 | CA2612080A1 Immediate-release therapeutic systems for improved oral absorption of 7-[(e)-t-butyloxyiminomethyl] camptothecin |
| 02/15/2007 | CA2583274A1 Enhancement of b cell proliferation by il-15 |
| 02/14/2007 | EP1752469A2 Long lasting fusion peptide inhibitors for HIV infection |
| 02/14/2007 | EP1752189A2 Microprojection array having a beneficial agent containing coating |
| 02/14/2007 | EP1752164A1 Percutaneous pharmaceutical preparation for external use containing nonsteroidal antiinflammatory analgesic |
| 02/14/2007 | EP1752162A1 Chronic articular inflammation-modulating composition based on collagen-polyvinylpyrrolidone |
| 02/14/2007 | EP1752160A2 Epitope sequences |
| 02/14/2007 | EP1752150A1 Irinotecan preparation |
| 02/14/2007 | EP1752142A2 Pegylated nanoparticles |
| 02/14/2007 | EP1752127A1 Process for producing edible oral administration preparation of aggregated substance-containing laminated film, and edible oral administration preparation of aggregated substance-containing laminated film |
| 02/14/2007 | EP1751225A2 Thermoplastic films and methods for making |
| 02/14/2007 | EP1751221A1 Embolization |
| 02/14/2007 | EP1751192A1 Cross-linked antibodies |
| 02/14/2007 | EP1751186A2 Carrier conjugates of tnf-peptides |
| 02/14/2007 | EP1750770A1 Use of organo-silicon compounds for constraining connective damaged tissues |
| 02/14/2007 | EP1750769A2 Methods for making injectable polymer hydrogels |
| 02/14/2007 | EP1750768A2 Use of targeted oxidative therapeutic formulation in bone regeneration |
| 02/14/2007 | EP1750767A1 Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| 02/14/2007 | EP1750761A1 Medical uses of carrier conjugates of non-human tnf-peptides |
| 02/14/2007 | EP1750756A2 Compositions and methods for enhanced mucosal delivery of parathyroid hormone |
| 02/14/2007 | EP1750755A1 Methods and formulations for increasing intestinal function |
| 02/14/2007 | EP1750750A1 Method of stabilizing proteins |
| 02/14/2007 | EP1750683A1 Sustained release formulations |
| 02/14/2007 | EP1750680A2 Controlled release press-coated formulations of water-soluble active agents |
| 02/14/2007 | EP1750679A1 Gel composition comprising charged polymers |
| 02/14/2007 | EP1750675A1 Stable oral pharmaceutical compositions of buprenorphine and derivatives |
| 02/14/2007 | EP1750671A1 Liposomal assembly for therapeutic and/or diagnostic use |
| 02/14/2007 | EP1750668A1 Liquids containing suspended glass particles |
| 02/14/2007 | EP1750666A2 Methods and articles for the delivery of therapeutic agents |
| 02/14/2007 | EP1750617A2 Agent eluting bioimplantable devices and polymer systems for their preparation |
| 02/14/2007 | EP1507514B1 Controlled release compositions of estradiol metabolites |
| 02/14/2007 | EP1505956B1 A method to improve surface properties of pharmaceutical tablets |
| 02/14/2007 | EP1485059B1 Topical dapsone for the treatment of acne |
| 02/14/2007 | EP1417228B1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 02/14/2007 | EP1414409B1 Stabilized oral suspension formulation |
| 02/14/2007 | EP1392756B1 Lipid-polymer-conjugates |
| 02/14/2007 | EP1287824B1 Member for application of ointment and ointment patch employing the same |
| 02/14/2007 | EP1280515B1 Pharmaceutical compositions comprising cannabis |
| 02/14/2007 | EP1272531B8 Crystalline mixtures of partial methyl ethers of beta-cyclodextrin and related compounds |
| 02/14/2007 | EP1246639B1 Glp-2 formulations |
| 02/14/2007 | EP1238664B1 Adhesive preparations |
| 02/14/2007 | EP1169069B1 Use of three-dimensional stromal tissue for the treatment of ischemic tissue |
| 02/14/2007 | EP1128813B1 An inhalation system |
| 02/14/2007 | EP1066030B1 Topical hormonal composition with systemic effect |
| 02/14/2007 | EP1009413B1 Use of immunostimulatory oligonucleotides for preventing or treating asthma |
| 02/14/2007 | EP0788346B9 Emulsified drug delivery systems |
| 02/14/2007 | CN1914222A Methods and compositions for identifying RNA-binding proteins |
| 02/14/2007 | CN1913925A Compositions comprising two different populations of polymer-active agent conjugates |
| 02/14/2007 | CN1913924A Solid sustained-releasing formulation comprising triptorelin acetate |
| 02/14/2007 | CN1913923A Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells |
| 02/14/2007 | CN1913917A Pharmaceutical composition for thrombin peptide derivatives |
| 02/14/2007 | CN1913912A Pharmaceutical compositions and methods for insulin treatment |
| 02/14/2007 | CN1913907A Use of ginkgo complexes for the enhancement of cognitive functions and the alleviation of mental fatigue |
| 02/14/2007 | CN1913903A Remedy for external use for skin and mucosal injuries caused by viral infection |
| 02/14/2007 | CN1913876A Drug-containing grains and solid preparation containing the grains |
| 02/14/2007 | CN1913875A Anionic hydrogel matrices with pH dependent modified release as drug carriers |
| 02/14/2007 | CN1912111A Engomphosis and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen |
| 02/14/2007 | CN1911470A Implantation micro-electrode having integrated medicinal agent releasing function, its manufacturing method and application |
| 02/14/2007 | CN1911450A Live target adjuvant containing D-galactose and sterol or aliphatic alcohol and its preparation |
| 02/14/2007 | CN1911449A Cholesterol phosphononucleoside analogue |
| 02/14/2007 | CN1911448A Zinc supplements based on cation exchange resin and its preparation method and use |
| 02/14/2007 | CN1911447A Transferrin-polyethylene glycol medicine molecular compound and its use |
| 02/14/2007 | CN1911446A Process for producing nanoparticles of paclitaxel and albumin |
| 02/14/2007 | CN1911438A 血管新生诱导剂 Angiogenic inducer |
| 02/14/2007 | CN1911244A Slow-released type iron-complement agent, prepn. method and use thereof |
| 02/14/2007 | CN1911243A Method for preparing platinum metal bunch with biological activity, and use thereof |
| 02/14/2007 | CN1911242A Carried-type active platinum metal bunch, prepn. method and use thereof |
| 02/14/2007 | CN1911241A Slow-released type iodine complement agent, and prepn. method and use-thereof |
| 02/14/2007 | CN1911239A Selenium-complement agent, and prepn. method and use thereof |
| 02/14/2007 | CN1911216A Medicated chitin fiber for treating and preventing proliferation of mammary gland, prepn. method and application thereof |
| 02/14/2007 | CN1911214A Method for preparing large quantity of micro-capsule |
| 02/14/2007 | CN1911213A Soft capsule of atovastatine salts and prepn. method therefor |
| 02/14/2007 | CN1911210A Dispersing tablets of nizatidine, and its prepn. method |
| 02/14/2007 | CN1911209A Quick-disintegration tablets of calcium atovastatine, and its prepn. method |